Serina Therapeutics (SER) Non Operating Income (2018 - 2026)
Serina Therapeutics (SER) posted Non Operating Income of $2.9 million for Q4 2025, up 60.77% sequentially from $1.8 million in Q3 2025, and up 3.29% YoY from $2.8 million in Q4 2024.
Serina Therapeutics (SER) Non Operating Income (2018 - 2026) Analysis & Trends
Serina Therapeutics has reported Non Operating Income for 8 years, with the latest figure at $2.9 million in Q4 2025.
- Quarterly Non Operating Income rose 3.29% year-over-year to $2.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.8 million (down 17.39% YoY) and the FY2025 annual result came in at $4.8 million, down 17.39% from the prior year.
- Non Operating Income grew to $2.9 million in Q4 2025 per SER's latest filing, from $1.8 million in the prior quarter.
- Over five years, Non Operating Income peaked at $9.0 million in Q2 2024 and troughed at -$12.7 million in Q1 2024.
- A 5-year average of $743400.0 and a median of $502000.0 in 2021 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2021 and 2024: Non Operating Income jumped 746.67% in 2021, then tumbled 584.5% in 2024.
- Over 5 years, Non Operating Income stood at -$292000.0 in 2021, then slumped by 235.27% to -$979000.0 in 2022, then soared by 182.74% to $810000.0 in 2023, then surged by 245.31% to $2.8 million in 2024, then increased by 3.29% to $2.9 million in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered $2.9 million, $1.8 million, and -$897000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Serina Therapeutics | 46.70 Mn | 23.67 Mn | - | 428,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 428,000.00 |
| Dec 31, 2025 | 2.89 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | -897,000.00 |
| Mar 31, 2025 | 1.04 Mn |
| Dec 31, 2024 | 2.80 Mn |
| Sep 30, 2024 | 6.70 Mn |
| Jun 30, 2024 | 9.04 Mn |
| Mar 31, 2024 | -12.69 Mn |
| Dec 31, 2023 | 810,000.00 |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 1.75 Mn |
| Mar 31, 2023 | 2.62 Mn |
| Dec 31, 2022 | -979,000.00 |
| Sep 30, 2022 | -886,000.00 |
| Jun 30, 2022 | -1.03 Mn |
| Mar 31, 2022 | -655,000.00 |
| Dec 31, 2021 | -292,000.00 |
| Sep 30, 2021 | -281,000.00 |
| Jun 30, 2021 | -270,000.00 |